Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Oncology

Biomedical/pharma, Neurology, Oncology

Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease

Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The company initially focused on treating Charcot-Marie-Tooth disease, and recently added a major indication to their lead program after finding strong evidence that their drug candidate can also reverse nerve damage caused by chemotherapy. Augustine Therapeutics aims to initiate clinical trials by 2024.

Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications

Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints Gerhard Koenig as Chairman of the Board. The company also expands the Scientific Advisory Board with clinical experts to support broader therapeutic applications, exploring the potential of novel HDAC6 inhibitors in Charcot-Marie-Tooth disease (CMT), and now also in other indications such as chemotherapy-induced peripheral neuropathy (CIPN), and amyotrophic lateral sclerosis (ALS).

IBA and SCK CEN partnership to produce rare radioisotope for cancer treatments

The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to enable large-scale production of the rare substance. A collaboration between IBA – the world’s leading company in particle accelerator technology – and the Belgian Nuclear Research Center (SCK CEN) now makes this crucial step possible. The partners are constructing a production plant on the SCK CEN site in the Flemish city of Mol.

Drug development trends: from common to orphan indications… and back again?

Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to niche populations. What has caused this trend, and is the pendulum of drug development swinging back again?

Abscint labels antibodies with radioactive material to spot harmful cells

Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.

V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals

ElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer

Mechelen, Belgium, January 25, 2022 - Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.

New start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster

The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies

Things are moving fast for Flamingo Therapeutics, a Leuven-based biotech company developing innovative RNA-targeted cancer therapies. The start-up is a pioneer in the field of lncRNAs, a large and untapped class of disease-causing targets within the so-called ‘dark matter’ of the human genome.

EsoBiotec ready to transform cell therapy cancer treatments

Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases

Cancer diagnosis and therapy in one: Precirix tackles tumors with camelid antibodies

A new drug that can identify tumors, trace metastases, and treat cancer – all in one? Belgian start-up Precirix is aiming high with its lead compound – a precision radiopharmaceutical using camelid antibodies to bind to, and irradiate, cancer cells.

Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics

Montis Biosciences appoints René Hoet as Chief Scientific Officer

Leuven, Belgium, 31 March 2021 - MONTIS BIOSCIENCES, a discovery stage biotech company focused on the development of novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, appoints René Hoet, Ph.D. as its Chief Scientific Officer. Dr Hoet brings extensive experience in antibody drug discovery and development, through his international career in Biotech and Pharma.

Saving man’s best friend: Volition blood test allows cheap and easy cancer screenings for dogs

A Belgian invention is revolutionizing cancer diagnostics for dogs by making it possible to screen for two common canine cancers with a simple, low-cost blood test. The innovation was developed by the Belgian subsidiary of Volition, a multinational company listed on the New York stock exchange. The company is also developing human blood tests for use in oncology as well as a number of other diseases including COVID-19.